Research for Hillstar Bio Announces the Formation of Clinical Advisory Board with Prominent Experts in Axial Spondyloarthritis and Autoimmune Disease Drug Development - aVenture Research
Hillstar Bio | Transforming Autoimmune Treatment
Hillstar Bio Announces the Formation of Clinical Advisory Board with Prominent Experts in Axial Spondyloarthritis and Autoimmune Disease Drug Development
BOSTON, Mass., September 10, 2025 – Hillstar Bio, a leading biotechnology company focused on developing next-generation precision immunology therapies for autoimmune diseases, today announced the formation of a Clinical Advisory Board (CAB) with leading physician-scientists in spondyloarthritis and rheumatology. The CAB will provide strategic guidance for the clinical development of HSB-101, Hillstar’s lead program targeting TRBV9 for the treatment of axial spondyloarthritis (AxSpA), for its tra